We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Probiotic Engineered To Restore Bile Salt Metabolism and Counter the Onset of Infection
News

Probiotic Engineered To Restore Bile Salt Metabolism and Counter the Onset of Infection

Probiotic Engineered To Restore Bile Salt Metabolism and Counter the Onset of Infection
News

Probiotic Engineered To Restore Bile Salt Metabolism and Counter the Onset of Infection

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Probiotic Engineered To Restore Bile Salt Metabolism and Counter the Onset of Infection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have created a probiotic to restore bile salt metabolism, found in the gastrointestinal tract, to counter the onset and effects of Clostridium Difficile Infection (CDI).


CDI is the infection of the large intestine or colon that leads to infectious diarrhoea, caused by an infectious bacterium known as Clostridium. Most cases of CDI have been observed to occur in those who have been taking antibiotics or just finished their course of antibiotics.


The administration of antibiotics in the treatment of CDI causes an imbalanced gut microbiome, known as dysbiosis, which can disrupt other microbiome processes such as bile salt metabolism.


The dysregulation of bile salt metabolism can activate dormant Clostridioides difficile spores, leading to CDI, causing severe diarrhoea and colitis – inflammation of the large intestine, or a reinfection of CDI.


A team of researchers, led by Associate Professor Matthew Chang, from the Synthetic Biology Translational Research Programme at NUS Medicine and NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), engineered a probiotic that can detect the occurrence of antibiotic-induced microbiome imbalance and express an enzyme that can regulate the bile salt metabolism upon detection.


This probiotic contains a genetic circuit that comprises a genetically encoded sensor, amplifier and actuator.


The team used an E. coli probiotic strain as the host because of its proven safety record in humans and its gram-negative nature makes it compatible with the current CDI therapy that uses antibiotics targeting gram-positive bacteria.


The sensor in this probiotic, detects the presence of sialic acid, a gut metabolite that is indicative of microbiome imbalance. The actuator produces an enzyme that can regulate the bile salt metabolism, activated by the sensor, and it reduces the germination of the Clostridioides difficile spores that causes CDI, when induced by the sialic acid sensor.


The team also included an amplifier in the probiotic which amplifies the activation by the sensor and increases the production of the enzyme, reducing the germination of the Clostridioides difficile spores by 98%. Experiments showed that the probiotic significantly reduced CDI in laboratory models, as demonstrated by a 100% survival rate and improved clinical outcomes.


Assoc Prof Chang says, “Our perspectives have shifted towards studying how we can come up an antimicrobial strategy to complement and assist the natural biological processes in the body to help limit the onset of infection. This is useful when considering the development or improvement of future therapeutics for CDI.”


Reference: Koh E, Hwang IY, Lee HL, et al. Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism. Nat Comms. 2022;13(1):3834. doi: 10.1038/s41467-022-31334-z.


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement